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Peroxisome proliferators activated receptors (PPARs) are ligand-activated nuclear transcription factors that play important roles
in lipid and glucose homeostasis. To the extent that PPAR agonists improve diabetic dyslipidaemia and insulin resistance, these
agents have been considered to reduce cardiovascular risk. However, data from murine models suggests that PPAR agonists also
have independent anti-atherosclerotic actions, including the suppression of vascular inﬂammation, oxidative stress, and activation
of the renin angiotensin system. Many of these potentially anti-atherosclerotic eﬀects are thought to be mediated by transrepres-
sion of nuclear factor-kB, STAT, and activator protein-1 dependent pathways. In recent clinical trials, PPARα agonists have been
shown to be eﬀective in the primary prevention of cardiovascular events, while their cardiovascular beneﬁt in patients with estab-
lished cardiovascular disease remains equivocal. However, the use of PPARγ agonists, and more recently dual PPARα/γ coagonists,
has been associated with an excess in cardiovascular events, possibly reﬂecting unrecognised ﬂuid retention with potent agonists
of the PPARγ receptor. Newer pan agonists, which retain their anti-atherosclerotic activity without weight gain, may provide one
solution to this problem. However, the complex biologic eﬀects of the PPARs may mean that only vascular targeted agents or pure
transrepressors will realise the goal of preventing atherosclerotic vascular disease.
Copyright © 2008 A. C. Calkin and M. C. Thomas. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. INTRODUCTION
Cardiovascular complications are the leading cause of pre-
mature mortality in patients with diabetes [1]. While clas-
sical risk factors for cardiovascular disease (CVD), such as
smoking, cholesterol, and hypertension, operate in persons
both with and without diabetes, the absolute risk of death is
2–4 times greater in patients with diabetes [2]a n dp r o g r e s -
sively larger with each additional risk factor [3]. Moreover,
CVD, cerebrovascular diseases, and peripheral vascular dis-
eases signiﬁcantly contribute to the morbidity in individuals
with diabetes [1]. Ultimately, these macrovascular complica-
tions will develop in more than half of the diabetic popula-
tion [1]. In primary care, over a third of all patients present-
ing with type 2 diabetes have an overt history of CVD, with a
similar number again likely to have undiagnosed macrovas-
cular disease [4]. Consequently, a key component (and some
wouldarguethemostimportantcomponent)inthemanage-
ment of diabetes is the primary and secondary prevention of
cardiovascular events.
Diabetes is said to act as an ampliﬁer of cardiovascular
risk leading to the increased incidence, size, and complex-
ity of atherosclerotic plaques [5, 6]. A number of compo-
nents contribute to accelerated atherosclerosis in diabetes.
Diabetic dyslipidaemia and insulin resistance signiﬁcantly
contribute to the development and progression of macrovas-
cular disease in diabetes. In addition, inﬂammation, oxida-
tive stress, enhanced matrix metalloproteinase activity, acti-
vation of the local renin angiotensin system (RAS), and the
accumulation of advanced glycation end-products (AGEs) in
thediabeticvasculaturealsoacttoenhanceatherogenesisand
impair plaque stability. Signiﬁcantly, each of these pathways
may be modiﬁed by the activity of peroxisome proliferator-
activated receptors (PPARs), ligand-activated nuclear tran-
scription factors with a diverse range of metabolic func-
tions [7–11]. This review will examine the actions of PPARs
in diabetes-associated atherosclerosis and explore the recent
controversies surrounding the actions of PPAR agonists on
CVD in patients with diabetes.
2. PEROXISOME PROLIFERATOR-ACTIVATED
RECEPTORS (PPARs)
PPARs are nuclear transcription factors that have com-
plex biological eﬀects, resulting from the transactivation or2 PPAR Research
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Figure 1:Transactivationandtransrepressioneﬀectsofperoxisome
proliferator-activated receptors.
transrepression of dozens of genes that play important roles
in glucose and lipid homeostasis [12]. Transactivation ef-
fects require ligand-activated dimerisation of PPAR with the
retinoid X receptor (RXR), followed by translocation of the
PPAR:RXRheterodimercomplextothenucleus,whereupon
it binds to PPAR response elements of target genes and in-
duces their expression [12]. Transrepression eﬀects are medi-
ated via interference with transcription factors such as acti-
vator protein-1 (AP-1) and nuclear factor-κB( N F - κB) [13]
(see Figure 1). In addition, conformational remodelling of
the PPAR receptor that follows ligand binding results in the
release of co-repressor molecules. The relative importance
of activation versus repression pathways for the in vivo ac-
tions of PPAR agonists remains to be established. Moreover,
thereisevidencethatallPPARligandsdonotstimulatetrans-
activation and transrepression pathways to a similar extent,
meaning that diﬀerent agents of the same class may have po-
tentially disparate eﬀects [14, 15].
Three diﬀerent PPAR isoforms have been identiﬁed in
humans. These share similar structural organization and se-
quence homology. However, these isoforms possess distinct
functions, and vary in their ligand aﬃnity, expression, and
activity in diﬀerent metabolic pathways.
3. PEROXISOME PROLIFERATOR-ACTIVATED
RECEPTOR ALPHA (PPARα)
PPARα is highly expressed in the vasculature, including the
endothelial cells [16, 17], smooth muscle cells [18], and
macrophages [19]. Activation of PPARα leads to modulation
of lipid metabolism, including transcription of apolipopro-
tein A1 (apoA1) [20] and apolipoprotein AII [21], result-
ing in increased levels of “cardioprotective” high-density
lipoprotein (HDL) cholesterol. Uptake of HDL cholesterol
is also increased via the upregulation of CLA-1/SR-B1 [22].
β-oxidation and lipoprotein lipase (LPL) activity are also
stimulated following activation of PPARα. This leads to a
decrease in triglycerides and free fatty acids, and levels of
apolipoprotein CIII, which inhibits LPL-mediated break-
down of triglycerides, further resulting in lower triglyceride
levels[23].Finally,low-densitylipoprotein(LDL)cholesterol
particles are shifted from a small, dense to a large, buoyant
form to create particles that are less atherogenic and more
easily cleared [24]. The natural ligands of PPARα include
prostaglandins, leukotrienes, and medium- and long-chain
free fatty acids such as eicosapentaenoic acid and docosa-
hexenoic acid [25, 26]. Synthetic ligands of this receptor are
utilized in the management of dyslipidaemia [27], and in-
clude members of the ﬁbrate drug class (e.g., gemﬁbrozil,
cloﬁbrate, fenoﬁbrate, and bezaﬁbrate).
4. PEROXISOME PROLIFERATOR-ACTIVATED
RECEPTOR GAMMA (PPARγ)
PPARγ is largely expressed in adipose tissue as well as in
skeletalmuscle,siteswherethisPPARisoformexertsmuchof
its metabolic actions [28]. However, PPARγ is also expressed
locally in the vasculature, including the endothelial cells
[17], smooth muscle cells [29], and macrophages [13, 19].
Broadly, PPARγ activation results in increased sensitivity to
the metabolic actions of insulin by reversing lipotoxicity-
induced insulin resistance. PPARγ activation has also been
shown to rejuvenate pancreatic β-cell function resulting in
their improved function [30]. In adipose tissue, activation
of PPARγ leads to diﬀerentiation of adipocytes, making
them more able to uptake fatty acids, in turn, sparing other
metabolic tissue such as skeletal muscle and liver [28]. In ad-
dition, PPARγ agonists increase the expression and activity
of glucose transporter-4 and phosphatidyl-3-kinase [31, 32].
The natural ligands of PPARγ include prostaglandins, such
as 15-deoxy-(12,14)-prostaglandinJ2, and fatty acids includ-
ing linoleic and arachidonic acids [32]. Synthetic ligands of
PPARγ include the thiazolidinedione drug class (e.g., rosigli-
tazone and pioglitazone). Some other drugs also have partial
agonist activity at the PPARγ receptor, including the AT1 re-
ceptor antagonist, telmisartan [33].
5. PEROXISOME PROLIFERATOR-ACTIVATED
RECEPTOR DELTA (PPARβ/δ)
The PPAR delta isoform (also known as beta) is the most
widely distributed of the PPARs, with expression seen in
most tissues including the vasculature [34]. Unlike the
other PPARs, PPARβ/δ-RXR heterodimers bind to consen-
sus PPAR DNA response elements in the absence of a ligand,
andrepresstargetgeneexpressionindirectlybyrecruitingco-
repressors [35]. Following ligand activation, the co-repressor
complex is disrupted, leading to enhanced PPARβ/δ target
gene expression by both ligand-induced transcriptional ac-
tivation and transcriptional derepression. In addition, re-
pressor molecules, such as BCL-6, are liberated on ligand
binding, leading to the repression of other pathways, such
as inﬂammation and the transcriptional activity of PPARα
and PPARγ [36, 37]. Because of its wide tissue expression,
it was initially suggested that PPARβ/δ might simply serve a
house-keeping role. However, more recent data suggest that
PPARβ/δ can play an important role in wound healing, in-
ﬂammatory responses, and lipid metabolism [34, 36]. ForA. C. Calkin and M. C. Thomas 3
example, PPARβ/δ activation has been shown to increase
H D Lc h o l e s t e r o ll e v e l sl i k eP P A R α ligands, as well as mediate
insulin-sensitising and glucose lowering eﬀects like PPARγ
[34, 38]. PPARβ/δ deﬁcient macrophages also show reduced
recruitment, which may be particularly important for plaque
stability [36] (see below). PPARβ/δ is activated by a large
variety of ligands, such as fatty acids and eiconsanoids in-
cluding prostaglandin A1, although the major natural lig-
and remains to be established [25]. Synthetic agonists with
nanomolar aﬃnities for PPARβ/δ have also been generated,
although none are currently used in clinical practice. In-
terestingly, the physiological action of these agonists in ex-
perimental atherosclerosis is similar to the phenotype ob-
served in PPARβ/δ knockout mice [36, 39], consistent with
the important actions of transcriptional de-repression fol-
lowing activation of PPARβ/δ.
6. PPAR AGONISTS AND DIABETIC DYSLIPIDAEMIA
Diabetic dyslipidaemia is a major reversible risk factor for
the prevention of CVD in individuals with diabetes [40]. A
range of quantitative and qualitative lipid and lipoprotein
abnormalities are observed in patients with diabetes [41].
The main components of diabetic dyslipidaemia are exces-
sive postprandial lipaemia associated with increased plasma
triglyceride[42],duetotheaccumulationofverylow-density
lipoprotein (VLDL), chylomicron remnants, and interme-
diate density lipoprotein particles in the plasma. This is
thought to reﬂect both the overproduction of triglyceride-
rich VLDL (due to increased ﬂux of free fatty acids and hep-
aticresistancetotheeﬀectsofinsulin),togetherwithreduced
catabolism (associated with reduced LPL activity) [43]. HDL
cholesterol levels are invariably reduced in patients with type
2 diabetes, reﬂecting increased catabolism of HDL parti-
cles [44]. In addition, HDL particles become enriched with
triglyceride, in an attempt to cope with an increased VLDL
burden. Although LDL cholesterol levels in patients with
type 2 diabetes are often within the normal range, there
remain signiﬁcant disturbances in LDL metabolism in dia-
betes. For example, LDL production is signiﬁcantly reduced,
while impaired turnover of LDL particles promotes glycox-
idative modiﬁcation of lipoprotein particles and cholesterol
deposition in the arterial wall [45–47]. Diabetes is also as-
sociated with the accumulation of small dense, triglyceride-
rich, LDL particles that have an increased atherogenic poten-
tial [24].
As noted above, both PPAR agonists are able to signiﬁ-
cantly modify circulating lipid levels, and therein reduce car-
diovascular risk in patients with diabetes [27, 48]. In par-
ticular, the use of ﬁbrates in patients with diabetes increases
HDL cholesterol, decreases triglyceride levels, and shifts LDL
cholesterol distribution toward larger, less atherogenic par-
ticles [24, 27, 49]. PPARγ agonists also stimulate reverse
cholesterol transport [50, 51] and have beneﬁcial eﬀects on
the low HDL cholesterol levels and elevated triglyceride lev-
els that characterize diabetic dyslipidaemia. However, thia-
zolidinediones can also modestly increase LDL cholesterol
levels in some patients [48]. PPARβ/δ agonists are able to
increase HDL cholesterol levels and improve postprandial
triglyceride clearance [52].
7. PPAR AGONISTS AND INSULIN RESISTANCE
While glycemic control is important for the prevention of
microvascular complications, its role in the development of
atherosclerotic vascular disease is less clear [53]. For exam-
ple, in the UKPDS study, macrovascular outcomes were not
correlated with HbA1c. However, CVD was reduced in pa-
tients that received the insulin sensitizer, metformin, when
comparedtoequivalentglycemiccontrolachievedbysulpho-
nylureas or insulin therapy [54]. This led to the hypothesis
that insulin sensitivity may itself play an important role in
the development of macrovascular disease, and that agents
that reduce insulin resistance, such as metformin and PPARγ
agonists, by extension, may have particular beneﬁts in the
management of type 2 diabetes [55]. Certainly, resistance to
the actions of insulin is strongly associated with CVD in pa-
tients with diabetes. To the extent that insulin resistance is
linked to chronic hyperglycaemia, dyslipidaemia, inﬂamma-
tion, and hypertension as part of the metabolic syndrome,
this association is not surprising. However, it is now clear
that insulin also has direct actions in the vasculature that
inﬂuence the development and progression of atheroscle-
rotic disease. For example, in diabetic tissues, selective in-
sulin resistance in the PI-3-kinase signaling pathway leads to
reduced synthesis of nitric oxide, impaired metabolic con-
trol,andcompensatoryhyperinsulinaemia.Atthesametime,
insulin signaling, via extracellular signal regulated kinase-
(ERK) dependent pathways, is relatively unaﬀe c t e di nd i a -
betes, meaning that hyperinsulinaemia is able to stimulate
the expression of endothelin and other pathogenic media-
tors, tipping the balance of insulin’s actions in favor of ab-
normal vasoreactivity, angiogenesis, and other pathways im-
plicated in atherosclerosis [56, 57]. In addition, preferential
impairmentofnon-oxidativeglucosemetabolismindiabetes
leadstoincreasedintracellularformationofAGEsandoxida-
tive stress. Nonetheless, while it is conceivable that improve-
ments in insulin sensitivity may have beneﬁcial vascular ef-
fectsin diabetes, thefactthatPPAR agonistsretain their anti-
atherosclerotic activity in the absence of insulin [9] suggests
that other (direct) actions may also be important for their
anti-atherosclerotic activities.
8. THE POTENTIAL DIRECT ANTI-ATHEROSCLEROTIC
ACTIONS OF PPAR AGONISTS
While improvements in metabolic control and the lipid pro-
ﬁ l eh a v ei m p o r t a n te ﬀects on CVD in patients with diabetes,
it is becoming increasingly clear that PPAR agonists have
a range of independent actions on the vascular wall which
impact on atherogenesis. In particular, pre-clinical studies
demonstrate ligand-dependent PPAR activation is able to
reduce the development and progression of atherosclerotic
lesions in a range of experimental models, without need-
ing to normalise dyslipidaemia and hyperglycaemia, or im-
prove insulin resistance [58]. For example, studies from
our group demonstrated that treatment with the PPARα4 PPAR Research
agonist, gemﬁbrozil, was able to prevent the accumulation
of atherosclerotic plaque in apolipoprotein E (apoE) knock-
out (KO) mice, a model in which PPARα agonists have no
eﬀect on severe dyslipidaemia [8]. Similarly, treatment with
the PPARγ agonist, rosiglitazone, in insulinopenic diabetic
apoE KO mice was also associated with a reduction in aor-
tic atherosclerosis [9], in the absence of insulin sensitization
or improvement in glucose levels. Finally, treatment with a
PPARβ/δ agonist, GW0742X, has also been shown to atten-
uate atherosclerosis in LDL receptor KO mice, in the absence
of changes in plasma lipids [39]. Taken together, these stud-
ies point to possible direct eﬀects of PPAR agonists on the
vasculature that impedes pathogenic pathways implicated in
the development of atherosclerosis, including inﬂammation,
oxidative stress, metalloprotease activity, AGE accumulation,
and activation of the RAS.
9. PPAR AGONISTS AND VASCULAR INFLAMMATION
Inﬂammation plays a key role in the development and pro-
gression of atherosclerotic vascular disease. Inﬂammatory
cells are a major component of early atherosclerotic le-
sions, and inﬂammatory cytokines and chemokines acceler-
ate plaque accumulation. Some of the earliest changes in-
volve the activation of endothelial cells, which then express
adhesion molecules such as vascular-cell adhesion molecule
1 (VCAM-1) [59], encouraging leucocyte recruitment, the
production of chemokines, and further inﬂammation. Acti-
vationofPPARreceptorshasalsobeenstronglylinked tothis
early inﬂammatory response. PPARα,γ and β/δ agonists re-
duce the expression of adhesion molecules, such as VCAM-
1, on the surface of cytokine-activated endothelial cells, as
well as reduce macrophage inﬁltration within atherosclerotic
plaque [8, 9, 60, 61]. PPAR agonists also reduce the produc-
tion of inﬂammatory cytokines including tumour necrosis
factor(TNF)-α,IL-6,andIL-1β [7,18].PPARαactivationin-
directly modulates inﬂammatory components in HDL, such
asapoA1,serumamyloidA,andparaoxonase-1[62].Thiazo-
lidinedionesarealsoabletoinhibitendothelialcellactivation
[63] and indirectly alter systemic inﬂammation by actions in
adipose tissue, reducing the production of pro-atherogenic
adipokines including TNF-α and resistin [64]. PPARβ/δ may
also have important anti-inﬂammatory actions. For exam-
ple, in LDLR KO mice treatment with the PPARβ/δ ago-
nist, GW0742X, was associated with a marked attenuation
of atherosclerosis, with a concomitant decrease in monocyte
chemoattractantprotein(MCP)-1andintercellularadhesion
molecule (ICAM)-1 [39].
10. PPAR AGONISTS AND OXIDATIVE STRESS
Oxidativestressisthoughttobeakeymediatorofatheroscle-
rosis,contributingtotheupregulationofadhesionmolecules
[65], acceleration of foam cell formation, and a reduction in
plaque stability [66]. PPAR agonists are also able to modu-
late oxidative stress in vascular tissues. PPARα activation re-
duces the expression of the pro-oxidant NAD(P)H subunit
p22phox, and increases endothelial expression of the anti-
oxidant, CuZn superoxide dismutase [67]. PPARγ agonists
also have potent anti-oxidant activity in human endothelial
cells [67], hypercholesterolemic rabbits [68], and obese sub-
jects[69].Studiesfromourlaboratoryhaveshownthattreat-
ment of diabetic animals with either a PPARα or a PPARγ
agonist is associated with a reduction in vascular superox-
ide production, together with reduced gene expression of
the NAD(P)H oxidase subunits p47phox and gp91phox ob-
served in the aorta of diabetic apoE KO mice [8, 9] (see
Figure 3).
11. PPAR AGONISTS AND MATRIX
METALLOPROTEINASES
Atherosclerotic plaque rupture, with subsequent occlusive
thrombosis,istheunderlyingcauseofsuddencardiacevents.
Matrix metalloproteinases (MMPs) are thought to mediate
the progression of atherosclerotic lesions to an unstable phe-
notype that is more prone to rupture, through the destruc-
tion of the overlying ﬁbrous cap. PPAR agonists may pro-
mote plaque stability by reducing the production of MMPs
from monocytes/macrophages and vascular smooth muscle
cells [70]. Our group has recently demonstrated that gemﬁ-
brozil treatment was associated with attenuation of diabetes-
associated MMP-2 and MMP-9 gene expression in aorta
of diabetic apoE KO mice [8]. Furthermore, studies in pa-
tients with type 2 diabetes and CVD have shown that treat-
ment with a PPARγ agonist is associated with a reduction in
plasma MMP-9 levels [11].
12. PPARs AND ADVANCED GLYCATION
END-PRODUCTS
The accumulation of AGEs, as a result of hyperglycaemia,
dyslipidaemia, and oxidative stress in diabetes, contributes
to the development and progression of vascular disease in
diabetes [71, 72]. AGEs accumulate in many diabetic tissues
[73], including in atherosclerotic plaques [71]. Their impor-
tance as downstream mediators of hyperglycaemia in dia-
betes has been amply demonstrated by animal studies using
inhibitorsofadvancedglycationtoretardthedevelopmentof
atherosclerotic vascular disease without directly inﬂuencing
plasma glucose levels [71, 74]. Furthermore, dietary excess
of AGEs has been shown to accelerate atherosclerosis with-
out aﬀecting glycemic control [75]. Recent studies suggest
that, in addition to lowering glucose levels, PPARγ agonists
are able to inhibit the formation of AGEs [76]. The mecha-
nism by which PPARγ agonists might reduce AGEs remains
to be established, although their anti-oxidant and lipid low-
ering activities may be relevant to AGE formation and the
advanced glycation pathway [10].
13. PPARs AND THE RENIN ANGIOTENSIN SYSTEM
The RAS has an important role in the development and pro-
gression of diabetic atherosclerosis. For example, our group
has demonstrated clear anti-atherosclerotic activity of RAS
blockade with an AT1 receptor antagonist or an angiotensin
converting enzyme (ACE) inhibitor in diabetic apoE KO
mice [77, 78]. PPAR activators are known to be negativeA. C. Calkin and M. C. Thomas 5
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Figure 2:Anincreaseinrenaltubulointerstitialareaassociatedwith
streptozotocin diabetes in apoE KO mice is attenuated following
treatment with PPARγ agonist, rosiglitazone, PPARα agonist, gem-
ﬁbrozil, or the dual PPARα/γ agonist, ragaglitazar.
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(c)
Figure 3: Cross-sections of aorta stained for the NAD(P)H oxidase
subunit, p47phox. ApoE KO mouse aorta from (a) control, (b) dia-
betic, and (c) diabetic + rosiglitazone treated mice.
regulators of the AT1 receptor gene. For example, our studies
with either rosiglitazone or gemﬁbrozil resulted in a signif-
icant reduction in the vascular expression of the AT1 recep-
tor in diabetic apoE KO mice (see Figure 4). At least in this
model, this repression of AT1 receptor expression by PPAR
agonistsmayfunction,intermsofatherogenesis,inanequiv-
alent manner to angiotensin receptor blockade.
14. PPARs AND THE DIABETIC KIDNEY
Chronic kidney disease is a major risk factor for cardiovas-
cular disease in patients with diabetes. For example, myocar-
dial infarction and stroke are 10 times more common in type
1 diabetic patients with kidney disease than those without
renal disease [79]. Below the age of 50 years, the excess of
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Figure 4: Gene expression of the angiotensin II subtype 1 receptor
as assessed by real-time RT-PCR in aorta from apoE knockout mice
treated with the PPARγ agonist, rosiglitazone or the PPARα agonist,
gemﬁbrozil for 20 weeks. P < .05 versus diabetic mice.
mortality from cardiovascular disease is almost entirely con-
ﬁned to patients with diabetic nephropathy [80]. Equally, in
patients with type 2 diabetes, the risk of developing cardio-
vasculardiseaseis2-3timeshigherinotherswithmicroalbu-
minuria compared to normal albumin excretion. In patients
with proteinuria, the risk is increased at least 10-fold [81].
PPAR agonists have a number of important actions in
the diabetic kidney, which may attenuate renal injury and
therein (indirectly) reduce cardiovascular risk. For example,
we have shown that albuminuria in streptozotocin-diabetic
mice is reduced by treatment with the PPARα agonist, gem-
ﬁbrozil, the PPARγ agonist, rosiglitazone, or the dual PPAR
agonist, compound 3q [82]. In addition, glomerulosclerosis,
tubulointerstitial expansion (see Figure 2), and collagen de-
position were signiﬁcantly attenuated. PPARγ agonists may
also have beneﬁcial actions on renal hypertrophy in mod-
elsofexperimentaldiabetes[83–85].Notably,theserenopro-
tective eﬀects are observed in the absence of changes in glu-
coseorlipidlevels,insulinsensitivity,orareductioninblood
pressure,andtakentogethersuggestsomeindependentreno-
protective action. Moreover, the ﬁnding of similar beneﬁcial
eﬀects of PPARα and PPARγ agonists, as well as thiazolidine-
dioneandnon-TZDdualagonistcompounds,raisesthepos-
sibility that neither of these agents are working through con-
ventional PPARα and γ pathways in this model, but through
the transrepression of other transcription factors implicated
in diabetic kidney disease including AP-1, signal transducers
and activators of transcription 1 (STAT-1) and NF-κB, even
in the absence of PPAR receptors [86]. Importantly, these re-
nal beneﬁts have also been observed in clinical trials with
PPAR agonists, including the recently completed FIELD trial
where a reduction in microalbuminuria was observed in pa-
tients treated with fenoﬁbrate [87]. Similarly, in the Diabetes
Atherosclerosis Interventional Study, fenoﬁbrate therapy was
associated withreducedprogression fromnormal urinary al-
bumin excretion to microalbuminuria in patients with type
2 diabetes [88]. Several previous studies have also demon-
strated that thiazolidinediones are able to improve markers6 PPAR Research
of renal structure and function in patients with diabetes
[89–91]. However, the cardioprotective beneﬁts of long-term
renoprotection observed in these studies remain to be estab-
lished.
15. CLINICAL TRIALS WITH PPARα AGONISTS
A number of clinical studies have shown that treatment with
lipid lowering agents is able to prevent adverse CVD out-
comes in patients with diabetes. Yet while PPARα agonists
are able to reduce lipid levels in patients with diabetes, their
clinicaleﬃcacyremainscontroversial,withanumberofboth
positive and equivocal results reported in clinical trials. For
example, in the Veterans Aﬀairs High-Density Lipoprotein
Intervention Trial (VA-HIT), patients with diabetes treated
with gemﬁbrozil had a reduced risk of a composite end point
ofcoronaryheartdisease(CHD)death,stroke,ormyocardial
infarction by 32% and reduced CHD deaths by 41% com-
pared to those with diabetes receiving standard care [92].
Moreover, the clinical beneﬁt derived from ﬁbrates exceeded
that attributable to changes in the lipid proﬁle. The Diabetes
Atherosclerosis Intervention Study (DAIS) showed that 3
years of treatment with fenoﬁbrate resulted in signiﬁcant re-
ductions in angiographic progression of atherosclerosis and
stenosis (P ≤ .03) [27]. Ciproﬁbrate therapy has also been
associated with an increase in ﬂow-mediated dilation in as-
sociationwithanimprovementinlipidproﬁleinpeoplewith
type 2 diabetes [49]. However, in the Helsinki Heart Study,
although gemﬁbrozil reduced the incidence of primary CHD
compared with placebo among patients with diabetes (3.4
versus 10.5%), this diﬀerence was not statistically signiﬁcant
[93]. Similarly, the recently published Fenoﬁbrate Interven-
tion and Event Lowering in Diabetes (FIELD) study demon-
strated a non-signiﬁcant 11% reduction in the primary end
point (coronaryartery disease (CAD) death or non-fatal my-
ocardial infarction (MI); P = .16) and an 11% reduction in
total cardiovascular events (P = .035) [87]. However, a 25%
reduction in total CVD events and coronary heart disease
events was observed in patients without a history of CVD (P
= .014). This possibly suggests that early and primary ther-
apy with PPARα agonists, comparable to the strategy em-
ployed in animal models and shown to be deﬁnitively anti-
atherosclerotic, may also be beneﬁcial in the clinical setting.
In addition, improvements in microvascular outcomes, in-
cludingareductioninmicroalbuminuriaintheFIELDstudy,
wouldbeexpectedtohavelong-termmacrovascularbeneﬁts.
16. CLINICAL TRIALS WITH PPARγ AGONISTS
Thiazolidinediones have been shown to have a range of posi-
tive eﬀects on vascular function in clinical studies. For exam-
ple, small clinical studies have demonstrated positive eﬀects
of thiazolidinediones on cardiovascular parameters such as
acetylcholine-mediated dilation [94] and pulse wave veloc-
ity [11, 95–97]. Whether such beneﬁts translate to a reduc-
tion in cardiovascular risk has been tested in several recent
and ongoing clinical trials, although these short-term studies
maybeinadequatetoassessaprocesslikeatherosclerosisthat
takes many decades to evolve.
The Prospective Pioglitazone Clinical Trial in Macrovas-
cular Events (PROACTIVE trial) examined the eﬀect of pi-
oglitazone, taken in addition to conventional therapy for
three years, on all-cause mortality, non-fatal MI, stroke,
acute coronary syndrome, leg amputation, and coronary or
leg revascularisation [98]. While there was a non-signiﬁcant
10% reduction in this primary outcome P = .09, the main
secondary endpoint (composed of all-cause mortality, non-
fatalMI,andstroke)wasreducedby16%(P =.03).However,
heart failure and symptomatic oedema due to ﬂuid retention
due to PPARγ agonists may have masked any beneﬁt from
actions on atherogenesis.
A recent meta-analysis has also been performed to exam-
ine the cardiovascular eﬀects of the PPARγ agonist, rosigli-
tazone, which includes outcome data from 35 trials, such as
the large Diabetes Reduction Assessment with Ramipiril and
Rosiglitazone Medication (DREAM) trial and the A Diabetes
Outcome Prevention Trial (ADOPT) [99–101]. This meta-
analysis demonstrated that treatment with rosiglitazone in-
creased the risk for MI by 43% (P = .03), and death from
cardiovascular causes by 64% (P = .06). Whether this ﬁnd-
ing also reﬂects increased ﬂuid retention remains to be es-
tablished.
17. THE PROMISE OF DUAL α/γ PPAR AGONISTS
The apparent eﬃcacy of PPARα and PPARγ agonists individ-
ually on metabolic control, led to the development of dual
PPARα/γ agonists, oﬀering the potential of optimising the
metabolic and anti-atherosclerotic actions arising from ac-
tivating both receptors. In general, these agents proved to
be more potent agonists of PPARγ than conventional thia-
zolidinediones and highly eﬀective at improving metabolic
parameters. For example, ragaglitazar was more eﬀective at
improvingglycemiccontrolandattenuatingplasmalipidlev-
els than single agonists such as rosiglitazone [102]. Simi-
larly, treatment with muraglitazar in db/db mice was more
eﬀective at reducing plasma glucose levels than rosiglitazone
[103]. Yet despite improved metabolic outcomes, the eﬀects
on atherogenesis have been less clear. For example, we found
that treatment with the dual PPARα/γ agonist, compound 3q,
was associated with a marked increase in atherosclerosis in
control apoE KO mice [104] (see Figure 5), while PPARγ
and α agonists used alone in this model were protective
[8, 9]. This increase in atherosclerotic plaque was observed
in control animals despite an improvement in glycemic con-
trol and an improvement in lipid proﬁle [104]. Further-
more, plaque accumulation in mice treated with the dual
PPAR compound was also associated with a concomitant
increase in aortic gene expression of the pro-inﬂammatory
molecules, P-selectin, CD36, VCAM-1, and MCP-1 and in-
creased macrophage inﬁltration, an eﬀect not seen with the
single PPAR agonists, rosiglitazone or gemﬁbrozil [104]. By
contrast, Claudel and colleagues demonstrated that treat-
ment with the dual PPARα/γ compound, GW2331, for 11
weeks was more eﬀective at attenuating atherosclerosis in fe-
maleapoE KO micethan rosiglitazone alone [105].Similarly,
Zuckerman et al. found that LY465608 reduced atheroscle-
rosis in male apoE mice fed a high-fat diet in the absenceA. C. Calkin and M. C. Thomas 7
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Figure 5:Totalaorticplaqueareaasassessedbyanenfaceapproach
inapoEknockoutmicetreatedwiththedualPPARα/γ agonist,com-
pound 3q for 20 weeks. P < .05 versus control mice.
of changes in plasma total cholesterol levels [106]. More re-
cently, the anti-atherosclerotic actions of tesaglitazar on vas-
cular disease have also been investigated. In apoE∗Leiden
mice fed a high-fat diet, tesaglitazar was associated with a
92% reduction in aortic atherosclerosis in association with
a reduction in macrophages and collagen in lesions [107]. In
high-fat fed LDL receptor KO mice treatment with tesagli-
tazar for 12 weeks was associated also with a decrease in
atherosclerosis in female mice in the absence of alterations
in cholesterol or triglyceride levels or a reduction in the in-
ﬂammatory markers serum amyloid A and serum amyloid P
[108]. The reasons for these conﬂicting results are unclear.
However, it is possible that the diﬀerent balance of activation
of PPARα and γ with each of these agents, as well as diﬀeren-
tial eﬀects on transrepression may have contributed to these
disparate ﬁndings.
18. CLINICAL STUDIES WITH DUAL PPAR AGONISTS
Despite their clear actions as PPARγ and PPARα agonists,
and clinical eﬃcacy in terms of lipid and glycemic control
[109–116], which were comparable or better than achieved
by PPAR agonist alone, recent reports have suggested that
dual PPARα/γ agonists may also be associated with an in-
creased risk of adverse cardiovascular events when used by
individuals with diabetes [116]. In particular, the risk of
death, myocardial infarction, stroke, transient ischaemia at-
tack, or CHF was increased by over two-fold (RR 2.62; 95%
CI 1.36 to 5.05) in patients with type 2 diabetes receiving
the dual agonist, muraglitazar, compared to those receiving
aP P A R γ agonist (pioglitazone) alone, despite comparable
eﬀects on glycemic control [116]. Whether this increase in
events is due to an augmentation of atherogenesis, as ob-
served in our pre-clinical models, or the by-product of aug-
mented ﬂuid retention in patients with a stiﬀ vasculature, re-
mains to be established. Certainly, the more potent activa-
tion of the PPARγ receptor achieved by dual agonists may
lead to clinically important ﬂuid retention in some patients,
particularly at high doses or in patients with established con-
gestive heart failure. Nonetheless, even when patients with
NYHA III/IV heart failure were excluded from these trials,
the muraglitazar treated group still had 13 adjudicated cases
ofheartfailurecomparedwithonlyonepatientinthecontrol
group. More recently, the development tesaglitazar has been
discontinued due to concerns about increased serum crea-
tinine and decreased glomerular ﬁltration rate [117]. Taken
togetherwithreportsoftoxicityandcarcinogeniceﬀectswith
some of the dual PPAR agonists in pre-clinical studies [118–
120], these ﬁnding have meant that ongoing evaluation of
this class of drug has been delayed and largely superseded by
the pan-PPAR agonists (detailed below).
19. THE DEVELOPMENT OF PAN-PPAR AGONISTS
The clinical eﬃcacy of PPAR agonists individually have led
to the development of chemical ligands with activity across
all three receptor isoforms. The potential advantage of such
a combination rests in the ﬁnding that these so-called “pan-
PPAR” agonists retain their broad metabolic activity, with-
out the weight gain associated with PPARγ agonists [121,
122]. Cell culture and pre-clinical studies have also demon-
strated the eﬃcacy of pan PPAR agonists in modulating var-
ious pathways linked to the development of atherosclerosis
[67, 123, 124].
20. CLINICAL STUDIES WITH PAN PPAR AGONISTS
There are a small number of pan-PPAR agonists now
in the early stages of clinical trials including GW766954,
GW625019, PLX-204, and netoglitazone (MCC-555) [125].
T h e s ea g e n t sh a v eb e e ns h o w nt oi m p r o v eg l y c a e m i ca n d
lipid control in a range of settings. While such beneﬁts
should confer some cardiovascular beneﬁt, the actions of
agents of this class on the development and progression of
atherosclerosis in diabetes remain to be established. How-
ever, some insight into the possible eﬃcacy of pan PPAR
agonists may be inferred from clinical studies using bezaﬁ-
brate. Although originally classed as a ﬁbrate, bezaﬁbrate is
now considered a pan-PPAR agonist, albeit of low potency.
Nonetheless,likeotherPPARagonists,treatmentwithbezaﬁ-
brate signiﬁcantly raises HDL cholesterol levels, reduces
triglycerides, and improves insulin sensitivity in patients
with diabetes [126]. In the Bezaﬁbrate Coronary Atheroscle-
rosis Intervention Trial (BECAIT) of dyslipidemic males un-
der the age of 45 who have experienced a previous MI,
bezaﬁbrate improved dyslipidaemia, reduced the cumula-
tive coronary event rate (P = .02) and slowed the progres-
sion of focal coronary atherosclerosis. The St Mary’s, Eal-
ing, Northwick Park Diabetes Cardiovascular Disease Pre-
vention (SENDCAP) trial also demonstrated a reduction in
the combined incidence of ischemic change on resting ECG
a n dd o c u m e n t e dM I[ 127]. Despite this, they were unable to
seeanyeﬀectofbezaﬁbrateontheprogressionofcoronaryof
femoral atherosclerosis over the 3 years of the study. By con-
trast, the Bezaﬁbrate Infarct Prevention (BIP) study demon-
strated no signiﬁcant eﬀect of bezaﬁbrate on fatal or non-
fatal MI in those with diabetes [128]. Whether newer and
more potent pan-PPAR ligands with diﬀerentialactivation of
the various PPAR isoforms will prove to be more beneﬁcial8 PPAR Research
with respect to cardiovascular outcomes remains to be estab-
lished. In addition, given the actions of PPAR in the tran-
scriptional regulation of an enormous range of genes and
pathways,thepotentialadverseimpactofsuchpan-PPARac-
tivity needs to be carefully studied.
21. CONCLUDING REMARKS
Agonists of the PPAR family have represented the most im-
portantdevelopmentinthemanagementofdiabetesoverthe
last decade. Despite the promise of improved insulin sensi-
tivity and better lipid control, these agents have not achieved
the cardiovascular beneﬁts expected of them. There is little
doubt that in experimental models, PPAR agonists have clear
and independent anti-atherosclerotic actions, including the
suppression of vascular inﬂammation, oxidative stress, and
activation of the renin angiotensin system. Why this has not
translatedintoclinicalbeneﬁtremainstobefullyestablished.
It may be that longer-term follow up of clinical studies will
reveal statistically signiﬁcant results, as the long-term bene-
ﬁts of improved metabolic control are realized. Equally, the
complex biological eﬀects of the PPARs in a range of or-
gans may mean that any beneﬁts are oﬀset by unwanted ac-
t i o n st h a ti m p a c to nC V D ,s u c ha sﬂ u i dr e t e n t i o n ,m a l i g -
nancy, renal impairment, or increases in LDL cholesterol.
Whether more organ-targeted agonists or pan-PPAR ago-
n i s t sw i l lp r o v em o r ee ﬀective remains to be seen.
However, the fact that many of the potentially useful vas-
culareﬀectsarethoughttobemediated bytransrepressionof
pro-atherogenic signalling pathways, should lead in the fu-
ture to the development of more selective transrepressors for
the prevention and management of cardiovascular disease in
diabetes.
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